Cargando…

Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study

Detalles Bibliográficos
Autores principales:	Guglielmelli, Paola, Ghirardi, Arianna, Carobbio, Alessandra, Masciulli, Arianna, Maccari, Chiara, Mora, Barbara, Rumi, Elisa, Triguero, Ana, Finazzi, Maria Chiara, Pettersson, Helna, Paoli, Chiara, Mannelli, Francesco, Vanni, Daniele, Rambaldi, Alessandro, Passamonti, Francesco, Alvarez-Larràn, Alberto, Andreasson, Bjorn, Vannucchi, Alessandro M., Barbui, Tiziano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2022
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8791590/ https://www.ncbi.nlm.nih.gov/pubmed/34753179 http://dx.doi.org/10.1182/bloodadvances.2021006006

Ejemplares similares

Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score
por: Barbui, Tiziano, et al.
Publicado: (2022)

Clinical outcomes under hydroxyurea treatment in polycythemia vera: a systematic review and meta-analysis
por: Ferrari, Alberto, et al.
Publicado: (2019)

A multistate model of survival prediction and event monitoring in prefibrotic myelofibrosis
por: Carobbio, Alessandra, et al.
Publicado: (2020)

Different effect of hydroxyurea and phlebotomy on prevention of arterial and venous thrombosis in Polycythemia Vera
por: Barbui, Tiziano, et al.
Publicado: (2018)

Incidence of solid tumors in polycythemia vera treated with phlebotomy with or without hydroxyurea: ECLAP follow-up data
por: Ghirardi, Arianna, et al.
Publicado: (2018)

Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis
por: Guglielmelli, Paola, et al.
Publicado: (2020)

A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea
por: Verstovsek, Srdan, et al.
Publicado: (2014)

Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases
por: De Stefano, Valerio, et al.
Publicado: (2018)

Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea
por: Pacilli, Annalisa, et al.
Publicado: (2018)

Survival expectation after thrombosis and overt-myelofibrosis in essential thrombocythemia and prefibrotic myelofibrosis: a multistate model approach
por: Carobbio, Alessandra, et al.
Publicado: (2023)

Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera
por: Carobbio, Alessandra, et al.
Publicado: (2022)

Response to: Ruxolitinib withdrawal due to the COVID-19
por: Barbui, Tiziano, et al.
Publicado: (2021)

High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib
por: Barbui, Tiziano, et al.
Publicado: (2021)

Prefibrotic myelofibrosis: treatment algorithm 2018
por: Finazzi, Guido, et al.
Publicado: (2018)

Differential prognostic impact of cytopenic phenotype in prefibrotic vs overt primary myelofibrosis
por: Coltro, Giacomo, et al.
Publicado: (2022)

P1041: LEUKOCYTOSIS SELECTS A SUBGROUP OF LOW-RISK PV PATIENTS IN WHOM PHLEBOTOMY-ALONE MAY BE INSUFFICIENT
por: Carobbio, Alessandra, et al.
Publicado: (2023)

Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives
por: Vannucchi, Alessandro M, et al.
Publicado: (2009)

Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera
por: Lussana, Federico, et al.
Publicado: (2017)

An agenda for future research projects in polycythemia vera and essential thrombocythemia
por: Barbui, Tiziano, et al.
Publicado: (2020)

Impaired response to first SARS‐CoV‐2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib
por: Guglielmelli, Paola, et al.
Publicado: (2021)

Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients
por: Mora, Barbara, et al.
Publicado: (2019)

A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis
por: Maffioli, Margherita, et al.
Publicado: (2022)

A Phase Ib Dose-finding Study of Panobinostat and Ruxolitinib in Myelofibrosis
por: Harrison, Claire, et al.
Publicado: (2022)

Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure
por: Harrison, Claire N., et al.
Publicado: (2020)

Integration of multiparameter flow cytometry score improves prognostic stratification provided by standard models in primary myelofibrosis
por: Mannelli, Francesco, et al.
Publicado: (2022)

The CYTO-PV: A Large-Scale Trial Testing the Intensity of CYTOreductive Therapy to Prevent Cardiovascular Events in Patients with Polycythemia Vera
por: Marchioli, Roberto, et al.
Publicado: (2011)

Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real‐life setting: An Italian MYNERVA Project
por: Coltro, Giacomo, et al.
Publicado: (2023)

JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis
por: Guglielmelli, Paola, et al.
Publicado: (2021)

Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts
por: Tefferi, Ayalew, et al.
Publicado: (2018)

ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera
por: Guglielmelli, Paola, et al.
Publicado: (2022)

Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project
por: Barraco, Daniela, et al.
Publicado: (2018)

Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low‐, intermediate‐1‐, intermediate‐2‐, and high‐risk myelofibrosis in JUMP, a Phase 3b, expanded‐access study
por: Passamonti, Francesco, et al.
Publicado: (2021)

Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia
por: Barbui, T, et al.
Publicado: (2015)

Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study
por: Cervantes, Francisco, et al.
Publicado: (2021)

Correction: Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study
por: Cervantes, Francisco, et al.
Publicado: (2021)

Cerebral venous thrombosis and myeloproliferative neoplasms: A three‐center study of 74 consecutive cases
por: Gangat, Naseema, et al.
Publicado: (2021)

Ernest Hemingway /
por: Pascual, Arturo Marcelo
Publicado: (2001)

Ernest Hemingway
por: Young, Philip
Publicado: (1955)

Ernest Hemingway
por: Rovit, Earl
Publicado: (1971)

Ernest Blacker
Publicado: (1911)

Cannot write session to /tmp/vufind_sessions/sess_s52stuqr7dtsm33h7953uq1101